Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.